<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02661646</url>
  </required_header>
  <id_info>
    <org_study_id>5010</org_study_id>
    <nct_id>NCT02661646</nct_id>
  </id_info>
  <brief_title>Quality of Life Changes on Lower Extremity Lymphedema Patients Using an Advanced Pneumatic Compression Device (PCD)</brief_title>
  <official_title>Assessment of Quality of Life Changes on Lower Extremity Lymphedema Patients Using an Advanced Pneumatic Compression Device at Home</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tactile Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tactile Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of quality of life and symptoms changes in primary or secondary, unilateral or
      bilateral lower extremity lymphedema patients using an advanced pneumatic compression system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post-market, on label, multi-center, single arm, observational clinical trial of a
      prospective cohort of 300 subjects with primary or secondary, unilateral or bilateral, lower
      extremity lymphedema in the United States. All subjects will receive pneumatic compression
      treatment for 52 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life changes: Questionnaires</measure>
    <time_frame>12 weeks</time_frame>
    <description>Questionnaires to assess quality of life changes after 12 weeks of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lymphedema symptom changes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Questionnaires [Lymphedema Quality of Life Tool (LYMQOL)] to assess lymphedema. symptom changes after 12 weeks of treatment. LYMQOL includes sub-scores for Function (range 8-32), Appearance (range 7-28), Symptoms (range 5-20), and Mood (range 6-24) where lower scores represent a better outcome. It also includes an Overall QOL sub-score (range 0-10) where a higher score represents a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of lymphedema and venous related healthcare visits</measure>
    <time_frame>52 weeks</time_frame>
    <description>Comparison of the number of lymphedema and venous related health care visits the year preceding treatment and the during the 52 weeks while receiving treatment (or until study exit)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Limb circumference changes after 12 weeks and 52 weeks of treatment</measure>
    <time_frame>12 weeks and 52 weeks</time_frame>
    <description>Comparison of changes in limb circumference after 12 weeks and 52 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibrosis grading changes after 12 weeks and 52 weeks of treatment</measure>
    <time_frame>12 weeks and 52 weeks</time_frame>
    <description>Comparison of fibrosis grading (range Grade 0 to Grade 3, a lower grade represents a better outcome) after 12 weeks and 52 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of skin changes after 12 weeks and 52 weeks of treatment</measure>
    <time_frame>12 weeks and 52 weeks</time_frame>
    <description>Comparison of changes in the presence of skin conditions based on clinician observation after 12 weeks and 52 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphedema staging changes after 12 weeks and 52 weeks of treatment</measure>
    <time_frame>12 weeks and 52 weeks</time_frame>
    <description>Comparison of lymphedema staging (range Grade 0 to Grade 3, a lower grade represents a better outcome) after 12 weeks and 52 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life changes: Questionnaires</measure>
    <time_frame>24 weeks and 52 weeks</time_frame>
    <description>Questionnaires to assess quality of life changes after 24 weeks of treatment</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Lymphedema</condition>
  <arm_group>
    <arm_group_label>Advanced Pneumatic Compression Group</arm_group_label>
    <description>All study participants will receive treatment using an advanced pneumatic compression device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Advanced Pneumatic Compression Device</intervention_name>
    <description>Advanced Pneumatic Compression Device</description>
    <arm_group_label>Advanced Pneumatic Compression Group</arm_group_label>
    <other_name>Flexitouch system</other_name>
    <other_name>Flexitouch Plus</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary or secondary, unilateral or bilateral, lower extremity lymphedema patients using
        the Flexitouch system during a 52 week study period.

        *Note: Only Veteran's are eligible as this study is run through The Department of Veterans
        Affairs New York Harbor Healthcare System.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Diagnosis of primary or secondary, unilateral or bilateral, lower extremity lymphedema

          -  Ability and willingness to participate in all aspects of the study including following
             prescribed care

          -  Ability to provide informed consent

          -  Must have a prescription for the Flexitouch (Flexitouch system or Flexitouch Plus)

        Exclusion Criteria:

          -  Diagnosis of active or recurrent cancer, or less than 3 months at the time of initial
             evaluation from the completion of chemotherapy, radiation therapy or primary surgery
             for the treatment of cancer.

          -  Active skin or limb infection/inflammatory disease (acute cellulitis, or other
             uncontrolled skin or untreated inflammatory skin disease)

          -  Acute thrombophlebitis (in last 2 months)

          -  Pulmonary embolism within the previous 6 months

          -  Deep Vein Thrombosis (DVT) within the previous 3 months

          -  Severe peripheral artery disease (critical limb ischemia including ischemic rest pain,
             arterial wounds, or gangrene)

          -  Pulmonary edema

          -  Heart failure (acute pulmonary edema, decompensated acute heart failure)

          -  Patients with poorly controlled asthma

          -  Previous use of the study pneumatic compression device (PCD)

          -  Currently using multi-layer bandaging (MLB) unless bandages can be removed for limb
             circumference measurements

          -  Pregnant women or women of childbearing potential not on contraception

          -  Any condition where increased venous and lymphatic return is undesirable

          -  Currently participating in another medical device or drug clinical trial

          -  Signs of noncompliance at the week 4 visit including: using the device less than 3
             times per week and/or not attending the scheduled visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Maldonado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susy Peters</last_name>
    <email>speters@tactilemedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexa Bennett</last_name>
    <email>abennett@tactilemedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Connecticut Healthcare System - West Haven</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patty Fugal, MS</last_name>
      <phone>203-785-4855</phone>
      <email>patricia.fugal@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Naiem Nassiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA New Jersey Health Care System (VANJHCS)</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <zip>07018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Padberg, MD</last_name>
      <phone>973-676-1000</phone>
      <phone_ext>1208</phone_ext>
      <email>frank.padberg@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Celeste DeMarco, APN-C</last_name>
      <phone>(973) 676-1000</phone>
      <phone_ext>11898</phone_ext>
      <email>celeste.demarco@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Frank Padberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA NY Harbor Healthcare System - Brooklyn</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Maldonado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA NY Harbor Healthcare System - St. Albans</name>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <zip>11425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Maldonado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA NY Harbor Healthcare System - Manhattan</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thomas Maldonado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 18, 2016</study_first_submitted>
  <study_first_submitted_qc>January 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2016</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Swelling</keyword>
  <keyword>Leg Lymphedema</keyword>
  <keyword>Primary Lymphedema</keyword>
  <keyword>Secondary Lymphedema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

